Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha CognitionACOG -1.58%34 Equity-to-Asset is 0.83 as of Mar. 2026, which is 232% above its 10-year median of 0.25. GuruFocus rates ACOG with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Alpha Cognition ranks better than 70.83% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Alpha Cognition's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $57.46 Mil. Alpha Cognition's Total Assets for the quarter that ended in Mar. 2026 was $69.25 Mil.
Therefore, Alpha Cognition's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.83.
The historical rank and industry rank for Alpha Cognition's Equity-to-Asset or its related term are showing as below:
ACOG'
s Equity-to-Asset Range Over the Past 10 Years
Min: -3.61 Med: 0.25 Max: 0.84
Current: 0.83
During the past 6 years, the highest Equity to Asset Ratio of Alpha Cognition was 0.84. The lowest was -3.61. And the median was 0.25.
ACOG's Equity-to-Asset is ranked better than 70.83% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs ACOG: 0.83
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Alpha Cognition Equity-to-Asset Related Terms
Alpha Cognition Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Alpha Cognition's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACOG vs HURA, MENS, ENLV: Equity-to-Asset Comparison
For the Biotechnology subindustry, Alpha Cognition's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Cognition Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Cognition's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Alpha Cognition's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Alpha Cognition's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Cognition (ACOG) has a Equity-to-Asset of 0.83 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Alpha Cognition and its competitors. This is 232% above median its historical median of 0.25. According to the industry distribution chart, Alpha Cognition ranks #413 out of 1416 companies in the Biotechnology industry, placing it in the top 29.2%.
Is Alpha Cognition's Equity-to-Asset too high?
Alpha Cognition's current Equity-to-Asset of 0.83 is 232% above median its 10-year median of 0.25. The Biotechnology industry median Equity-to-Asset is 0.68. Alpha Cognition's value of 0.83 is 22.1% above this industry median. Based on the distribution chart, Alpha Cognition ranks #413 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alpha Cognition has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Cognition's Equity-to-Asset compare to HURA and MENS?
According to the Biotechnology industry distribution chart, Alpha Cognition ranks #413 out of 1416 companies for Equity-to-Asset. This puts Alpha Cognition in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Alpha Cognition's value of 0.83 is 22.1% above this benchmark. While the company's 10-year median is 0.25 vs. the industry median of 0.68, Alpha Cognition has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpha Cognition's current Equity-to-Asset of 0.83 is 22.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Alpha Cognition and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Cognition's current Equity-to-Asset is 0.83, which is 232% above median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Cognition stock overvalued right now?
Alpha Cognition (ACOG) has a current Equity-to-Asset of 0.83. The current Equity-to-Asset is 0.83, which is 232% above median its 10-year median of 0.25 and 22.1% above the Biotechnology industry median of 0.68. Alpha Cognition's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Alpha Cognition (ACOG), the current Equity-to-Asset is 0.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
34GF Score
Get the complete analysis for ACOG
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACOG has been successfully added to your 
